Zogenix Inc (ZGNX) - Financial and Strategic SWOT Analysis Review

  • ID: 4278387
  • SWOT Analysis
  • 59 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Amorsa Therapeutics Inc
  • Biocodex
  • GW Pharmaceuticals Plc
  • Xenon Pharmaceuticals Inc
  • MORE
Zogenix Inc (ZGNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the Author to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Zogenix Inc (Zogenix) is a pharmaceutical company with focus on central nervous system (CNS) disorders. It develops and commercializes therapies for rare CNS disorders. The company’s lead product candidate ZX008 (low dose fenfluramine) is intended for the treatment of Dravet syndrome and Lennox-Gastaut syndrome (LGS). ZX008 is in Phase 3 clinical trials and has orphan drug designation in the US and EU and secured Fast Track designation and breakthrough therapy designation from the US FDA. The company has operations in the UK through its subsidiary Zogenix International, Ltd. Zogenix is headquartered in Emeryville, California, the US.

Zogenix Inc Key Recent Developments

Sep 04, 2018: Zogenix Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Durable Reduction in Seizure Frequency in Patients With Lennox-Gastaut Syndrome[Newswire : Healthcare - GNW RSS]
Aug 30, 2018: Zogenix Announces New Data on Psychological and Socioeconomic Impact of Dravet Syndrome and Other Epileptic Encephalopathies at 13th European Congress on Epileptology
Aug 06, 2018: Zogenix provides corporate update and reports second quarter financial results
Jul 02, 2018: Zogenix Appoints Ashish Sagrolikar As New Global Chief Commercial Officer
May 09, 2018: Zogenix Provides Corporate Update and Reports First Quarter Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amorsa Therapeutics Inc
  • Biocodex
  • GW Pharmaceuticals Plc
  • Xenon Pharmaceuticals Inc
  • MORE
Section 1 - About the Company

Zogenix Inc - Key Facts
Zogenix Inc - Key Employees
Zogenix Inc - Key Employee Biographies
Zogenix Inc - Major Products and Services
Zogenix Inc - History
Zogenix Inc - Company Statement
Zogenix Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Zogenix Inc - Business Description
R&D Overview
Zogenix Inc - SWOT Analysis
SWOT Analysis - Overview
Zogenix Inc - Strengths
Zogenix Inc - Weaknesses
Zogenix Inc - Opportunities
Zogenix Inc - Threats
Zogenix Inc - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Zogenix Inc, Recent Deals Summary

Section 5 – Company’s Recent Developments

Sep 04, 2018: Zogenix Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Durable Reduction in Seizure Frequency in Patients With Lennox-Gastaut Syndrome[Newswire : Healthcare - GNW RSS]
Sep 04, 2018: Zogenix Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Durable Reduction in Seizure Frequency in Patients With Lennox-Gastaut Syndrome[Newswire : Healthcare - GNW RSS]
Sep 04, 2018: Zogenix Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Durable Reduction in Seizure Frequency in Patients With Lennox-Gastaut Syndrome[Newswire : Healthcare - GNW RSS]
Aug 06, 2018: Zogenix provides corporate update and reports second quarter financial results
May 09, 2018: Zogenix Provides Corporate Update and Reports First Quarter Financial Results
Mar 06, 2018: Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results
Nov 07, 2017: Zogenix Provides Corporate Update and Reports Third Quarter 2017 Financial Results
Aug 08, 2017: Zogenix Provides Corporate Update and Reports Second Quarter 2017 Financial Results
May 04, 2017: Zogenix Reports First Quarter 2017 Financial Results
May 04, 2017: Zogenix Q1 net loss increases

Section 6 – Appendixs

Methodology
Ratio Definitions
About
Contact Us
Disclaimer

List of Tables

Zogenix Inc, Key Facts
Zogenix Inc, Key Employees
Zogenix Inc, Key Employee Biographies
Zogenix Inc, Major Products and Services
Zogenix Inc, History
Zogenix Inc, Other Locations
Zogenix Inc, Subsidiaries
Zogenix Inc, Key Competitors
Zogenix Inc, Ratios based on current share price
Zogenix Inc, Annual Ratios
Zogenix Inc, Annual Ratios (Cont...1)
Zogenix Inc, Annual Ratios (Cont...2)
Zogenix Inc, Interim Ratios
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Zogenix Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Zogenix Inc, Performance Chart (2013 - 2017)
Zogenix Inc, Ratio Charts
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Zogenix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Xenon Pharmaceuticals Inc
  • GW Pharmaceuticals Plc
  • Biocodex
  • Amorsa Therapeutics Inc
  • Acadia Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll